MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
MetaVia's Phase 1 MAD data for DA-1726, a dual GLP-1/glucagon agonist, was accepted for an oral presentation at the Precision Liver Symposium 2026 on November 4 in Denver. The abstract title cites significant MRI-PDFF reduction and weight loss with relative lean-mass preservation in a randomized placebo-controlled trial; in the MAD trial, the 32 mg dose showed best-in-class potential for weight loss, glucose control, and waist circumference reduction.
Key figures
- Drug Name
- DA-1726
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.